Call for Abstracts for 2016 Pharmacy Research Conference – Deadline 30 June 2016

For the 
3rd Annual Pharmacy Research Conference 19th-20th July at the Taj Pamodzi Hotel, in Lusaka

THEME:  Reducing Disease Burden through Pharmaceutical Care and Research

The Ministry of Health in collaboration with CIDRZ and the WHO will host the 3rd Annual Pharmacy Research Conference in Lusaka. The conference will provide plenary sessions, panel discussions, oral and poster presentations, discussions on current pharmacy practice and an opportunity to share ideas for successful programmes and research studies that have worked in other healthcare systems.

Suitable Abstracts from Pharmacy Students (under and post-graduate), Pharmacy Technologists and Pharmacists are invited for oral and poster presentation relevant to the following topics:

  • Paediatric Care
  • Women’s Health
  • Operational Research
  • Pharmacovigilance
  • Clinical Pharmacy
  • Logistics and Supply Chain

Submission Deadline: 11:59 pm CAT June 30, 2016           

*Note that presenting an abstract is voluntary. 

  • All abstracts should be in English.
  • Incomplete or inaccurate abstracts will be rejected
  • No more than 02 abstracts per attendee: one oral and one poster.
  • Capitalize the first word of the title only
  • Provide a concise statement (max. 500 words) of the Background, Research Aims/Objectives, Methodology, Results/Findings and Conclusions. The title and author’s names are not included in the word limit.
  • Use Arial, 10pt font, single-spaced and left aligned. DO NOT use all caps.
    Use standard abbreviations only. Within the body of the abstract, spell out the name in full at the first mention and follow with the abbreviation in parenthesis. Abbreviations may be used in the title, provided the name in full is outlined in the body of the abstract.

To Submit your Abstract:
Email your completed abstract and the required information below to both:

Mr Boyd Mwanashimbala          0977 877 070
Ms Helen Bwalya Mulenga      0977 780 594

Please Include in your email:

  • Abstract Title
  • Topic – (max. 500 words) in the following format
    • Background
    • Research Aims/Objectives
    • Methodology
    • Results/Findings
    • Conclusions
  • Presenting Author, institutional affiliation, contact details, and email
  • Name and Organisation of Co-Authors in the order they should appear in the Abstract book
  • A brief biography (no more than 50 words) of the Presenting Author
    Indicate Oral or Poster preference

Abstract Evaluation Process and Criteria:
The Pharmacy Scientific Programme Committee will review abstracts beginning 1st July 2016. Abstracts not meeting the criteria below, as determined by the Pharmacy Scientific Programme Committee, will be rejected. The Committee will contact authors with formal acceptance or rejection notices as soon as possible. All notifications will be sent to the email address provided during the abstract submission process. The Committee will indicate the format of presentation: either oral or poster.

Abstracts will be evaluated based on the following criteria:

  • —Scientific merit
  • Direct relevance to the field of pharmacy
  • Submission of a clearly written, well organised abstract
  • Adherence to the submission guidelines outlined above

Dissemination of Abstracts:

Abstracts will be published in the 2016 Pharmacy Conference Book of Abstracts and disseminated to all conference attendees in electronic format.

Withdrawal of Submitted Abstract:

If you withdraw your Abstract submission, please email AND

Thank you for your interest in presenting at the conference

Head of Grants & Contracts

Reports to the Deputy Chief Executive Officer and is responsible for the oversight and management of all grants and contracts within CIDRZ.

Serves as the lead expert for the planning, implementation and evaluation of grant proposals and provides guidance on cooperative agreements, cost-share agreements, participating agreements, collection agreements, inter-agency and intra-agency agreements and Memoranda of Understanding.

Leads the development of organisational strategies through the identification of gaps and issues in grant proposals.

Main Duties:

  • Serves as a key liaison between CIDRZ and local and international partnering organisations
  • Responsible for ensuring professional relationships are maintained with all partners
  • Develops and implements new and revised grants management policies, directives, standards and procedures
  • Maintains current knowledge of relevant information sources and key landscape events which may impact policies and procedures and provides strategic input to senior management
  • Provides detailed explanations of finding and recommendations regarding compliance with grant documents and recommendations
  • Develops, analyses, and interprets grant and/or cooperative agreement policies, Standard Operating Procedures, and guidelines
  • Develops training, technical assistance and guidelines, and provides oversight, expertise and consultation to internal staff, management and programme officials, awardees, review panels, applicants, recipients, and sub-recipients
  • Independently analyzes grant requests and provides recommendations to management; may decline or approve grants
  • Ensures all required legal and financial paperwork is properly reviewed by the Compliance Officer and is in line with CIDRZ policies
  • Facilitates pre-award negotiations on matters such as terms and conditions of awards, costs, schedules, and oversight responsibilities


  • Master’s Degree in Business Administration/Accountancy or other relevant professional qualification with minimum of 7 years’ experience with private sector, NGO, or international organisation
  • Strong knowledge and training in U.S. Government, or other donor regulations and policies
  • Proven experience with budget development, monitoring and reporting, and strategic development
  • Demonstrates high degree of independence, requiring minimal supervision to accomplish complex project work assignments
  • Ability to proactively identify projects and initiatives, and eagerly accept challenges and new responsibilities
  • Ability to successfully interface with senior level colleagues in other organisations and maintain relationships with international partners

Suitably qualified candidates are invited to apply; only shortlisted candidates will be contacted.

Please send application letter quoting job title, relevant academic and professional certificates and detailed CV with day-time telephone to:

CIDRZ Director Human Resources
P. O. Box 34681, 
Plot 5032 Great North Road Lusaka

or Email:

Closing Date for applications 3rd December

Share this entry

Ronald Sinkala


Ronald Sinkala MSc, LLB, ACIS, AZICA is CIDRZ Company Secretary/Compliance Officer.

Ronald manages the CIDRZ Company Secretarial function performing the duties of Board Secretary. He provides administrative support to the Board Chair and Chief Executive Officer; identifies and monitors risk to the organisation and provides risk management with specific focus on legal, governance and donor compliance. He also drafts commercial and non-commercial contracts.

He has over 15 years’ experience managing donor-funded local and international institutions including Catholic Relief Services (CRS Zambia) serving as Head, Project Finance and Donor Reporting; the Netherlands Development Organization (SNV Zambia) serving as Country Controller, and the Churches Health Association of Zambia (CHAZ). Ronald is skilled at setting up internal controls, and developing policies and administration/financial management procedure manuals for sub-recipients.

He holds a MSc Finance from the London School of Business and Finance (with specialisation in Risk Management), and is a Chartered Secretary and Accountant registered with the Institute of Chartered Secretaries and Administrators (ICSA UK) and the Zambia Institute of Chartered Accountants (ZICA). He also holds a Law Degree (LLB) from the University of Zambia.

Zambian Prisons Health paper features in WHO STOP TB Partnership News Alert

Congratulations to the CIDRZ TB Department whose project and resulting paper, “Screening for tuberculosis and testing for human immunodeficiency virus in Zambian Prisons” feature in World Health Organization’s STOP TB Partnership News Alert. Read the paper here>>> [link to the paper]Congratulations to the CIDRZ TB Department whose project and resulting paper, “Screening for tuberculosis and testing for human immunodeficiency virus in Zambian Prisons” feature in World Health Organization’s STOP TB Partnership News Alert. Read the paper here>>> [link to the paper]

Age at antiretroviral therapy initiation predicts immune recovery, death, and loss to follow-up among HIV-infected adults in urban Zambia

AIDS Res Hum Retroviruses. 2014 Jul 6. [Epub ahead of print] 24998881

Vinikoor MJ, Joseph J, Mwale J, Marx MA, Mulenga L, Stringer JS, Eron JJ, Chi B


We analyzed the association of age at antiretroviral therapy (ART) initiation with CD4+ T-cell count recovery, death, and loss to follow-up (LTFU) among HIV-infected adults in Zambia.


We compared baseline characteristics of patients by sex and age at ART initiation (categorized as 16-29 years, 30-39 years, 40-49 years, 50-59 years, 60 years and older (P for trend<0.001). We used the medication possession ratio to assess adherence and analysis of covariance to measure the adjusted change in CD4+ T-cell count during ART. Using Cox proportional hazard regression, we examined the association of age with death and LTFU. In a secondary analysis, we repeated models with age as a continuous variable.


Among 92,130 HIV-infected adults who initiated ART, the median age was 34 years and 6,281 (6.8%) were aged ≥50 years. Compared with 16-29 year-olds, 40-49 year-olds (-46 cells/mm3), 50-59 year olds (-53 cells/mm3), and 60+ year-olds (-60 cells/mm3) had reduced CD4+ T-cell gains during ART. The adjusted hazard ratio (AHR) for death was increased for individuals aged ≥40 years (AHR 1.25 for 40-49 year-olds, 1.56 for 50-59 year-olds, and 2.97 for 60+ year-olds). Adherence and retention in care were poorest among 16-29 year-olds but similar in other groups. As a continuous variable, a 5-year increase in age predicted reduced CD4+ T-cell count recovery and increased risk of death.


Increased age at ART initiation was associated with poorer clinical outcomes, while age <30 years was associated with higher likelihood of being lost to follow-up. HIV treatment guidelines should consider age-specific recommendations.

GAVI Supported Rotavirus Vaccines Introduced in Zambia

Following a successful pilot program delivering rotavirus vaccines as part of an integrated approach to diarrhoea prevention and control, in November 2013, Zambia rolled out GAVI-supported rotavirus vaccines nationwide. Read more

Improving Equitable Access and Coverage of Hygiene and Sanitation Practices in Rural Communities

In the following write-up, Dr Roma Chilengi, CIDRZ’s Director of Health Systems and Primary Care highlights CIDRZ’s objectives in its sanitation programmes and the advantages of implementing the Community-Led Total Sanitation (CLTS) model.

CIDRZ has partnered with UNICEF to work with the Government of Zambia, to improve equitable access and coverage of hygiene and sanitation practices in the rural communities of Chongwe and Kafue districts. Through the implementation of Community-Led Total Sanitation (CLTS) and School-Led Total Sanitation (SLTS) programmes, CIDRZ will collaborate to ensure that:

  •  150,633 people have improved access to sanitation and hygiene facilities and have their own household latrines
  • 20,859 school children in 24 schools have improved access to sanitation and hygiene facilities through construction of 190 Ventilated Improved Pit Latrines with hand washing facilities

The ambitious goal of this programme is to objectively demonstrate that targeted villages attain Open Defecation Free (ODF) status”, that is, each household must have a toilet (with a lid and super structure), as well as a hand washing facility.

 Lessons Learnt

Such apparently simple interventions can help avert diarrhoeal disease if appropriately implemented. The CLTS model comes with several key lessons:

  • To be sustainable, communities themselves must build and own their own toilets
  • The involvement of traditional leaders, especially village headmen and chiefs as opposed to civic leaders is key
  • Use proven triggering process and ensure trained professionals verify and certify ODF status
  •  With appropriate strategies, ODF can be achieved in most rural places through cost efficient strategies
  • CLTS champions need to be recognised and made proud as agents of change.

Appropriate toilets and hand washing with soap are key transmission breakers for most causes of diarrhoeal diseases and CIDRZ not only recognizes that; it is in the forefront to support primary prevention; PREVENTION IS BETTER THAN CURE!

CIDRZ Researcher Groesbeck Parham awarded grant to study epidemiology of HPV and cervical cancer

CIDRZ researcher Professor Groesbeck Parham will lead the Zambian ‘EPIC’ biomarker study searching for a biomarker of persistent high-risk Human Papilloma Virus (HPV) infection as part of a grant to the African Collaborative Center for Microbiome and Genomics Research. The U.S. National Institutes of Health (NIH) recently announced the 4-year grant award of $4.16 million to support the work of the Institute of Human Virology in Nigeria, and CIDRZ, to better understand the epidemiology of HPV infection and cervical cancer. “Cancer of the cervix is the most common cancer in Africa. This grant will address a high-impact public health challenge that affects women’s health in Africa and the rest of the world,” NIH said.

The African Collaborative Center for Microbiome and Genomics Research (ACCME) is a multi-country, multi-institutional collaborative research group involving the Institutes of Human Virology Nigeria and CIDRZ in partnership with international organizations, including Institutes of Genome Sciences and Human Virology, Cambridge University, UK; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA; and the Center for Genomics and Global Health, National Human Genome Research Institute, Bethesda, Maryland, USA.

A controlled trial of three methods for neonatal circumcision in Lusaka, Zambia.


OBJECTIVE: Neonatal male circumcision (NMC) is not routinely practiced in Zambia, but it is a promising long-term HIV prevention strategy. We studied the feasibility and safety of three different NMC methods.

METHODS: We enrolled healthy newborns in a controlled trial of the Mogen, Gomco, and Plastibell devices. Doctors, nurses, and clinical officers were trained to perform Mogen, Gomco, and Plastibell techniques. Each provider performed at least 10 circumcisions using each device. Neonates were reviewed at 1 and 6 weeks after circumcision for adverse events.

RESULTS: Between October 2009 and March 2011, 17 providers (5 physicians, 9 nurse midwives, and 3 clinical officers) without previous NMC experience were trained, and 640 circumcisions were performed. The median infant birth weight was 3.2 kg (interquartile range: 2.9-3.5 kg), and median age at the time of procedure was 11 days (interquartile range: 7-18 days); 149 babies (23.3%) were exposed to HIV. The overall adverse event rate was 4.9% (n = 31/630), and the moderate-severe adverse event rate was 4.1% (n = 26/630). Rates did not significantly differ by method. Most providers (65%) preferred Mogen clamp over Gomco and Plastibell.

CONCLUSION: Doctors, nurses, and clinical officers can be trained to safely provide NMC in a programmatic setting. The 3 studied techniques had comparable safety profiles. Mogen clamp was the preferred device for most providers.

Authors: Bowa K, Li MS, Mugisa B, Waters E, Linyama DM, Chi BH, Stringer JS, Stringer EM.

Read the full-text article here